Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03964090 | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | active not recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04609046 | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | active not recruiting | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 |
| clinicaltrials |
| NCT04991870 | Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05978557 | Brain Slice Explants to Predict Drug Response in Brain Tumors | recruiting | — | 50 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06894225 | Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature | recruiting | Phase 2 | 12 | National Neuroscience InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07789678 | Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil(BRIGHT) | not yet recruiting | — | 350 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805096 | Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and Parents' Bio-Psycho-Social and Spiritual Health | recruiting | N/A | 120 | National Defense Medical University, TaiwanOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02337686 | Pembrolizumab in Treating Patients With Recurrent Glioblastoma | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02679144 | Neuroblastoma Maintenance Therapy Trial(NMTT) | active not recruiting | Phase 2 | 441 | Giselle ShollerOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT04301843 | Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | active not recruiting | Phase 2 | 131 | Giselle ShollerOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT04677049 | Study of Niacin in Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 59 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06540963 | Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | recruiting | Phase 2 | 98 | Giselle ShollerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 104 | Milton S. Hershey Medical CenterOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06959979 | Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma | recruiting | Early Phase 1 | 60 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07110246 | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas(PNOC037) | recruiting | Phase 2 | 96 | University of California, San FranciscoOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07356973 | Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma(OPTICAL) | recruiting | Phase 2 | 147 | CRISM Therapeutics LTDINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07358260 | B7-H3.CD28Z.CART in Solid Tumors | recruiting | Phase 1 | 40 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07384884 | Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas(SLITT-GBM) | recruiting | N/A | 12 | King's College Hospital NHS TrustOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07390539 | B7-H3.CD28Z.CART in CNS Neoplasms | recruiting | Phase 1 | 70 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07441707 | A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours | active not recruiting | Phase 1 | 6 | IpsenINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07539441 | A Study of Mirdametinib in People With Central Nervous System Tumors | recruiting | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | recruiting | Phase 2 | 124 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06222203 | Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | recruiting | — | 225 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06594315 | Assessing Brain Metabolism Using MRS With Deuterated Glucose | recruiting | — | 80 | University of California, San FranciscoOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06762080 | Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 36 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06809530 | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | recruiting | Phase 3 | 408 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07799623 | Ciprofol, Propofol and Sevoflurane for Postoperative Delirium in Elderly Brain Tumor Patients | not yet recruiting | N/A | 381 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02114229 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors(SJATRT) | active not recruiting | Phase 2 | 125 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03678389 | Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery | recruiting | N/A | 70 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04637503 | 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | active not recruiting | Phase 1 | 103 | PfizerINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07242963 | Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study | recruiting | — | 300 | Mohammad H. Abu ArjaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07797660 | A Study for Postoperative Delirium in Older Patients With Intracranial Tumors | not yet recruiting | — | 164 | Beijing Tiantan HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04145115 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | active not recruiting | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT05226494 | Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma | active not recruiting | Phase 1 | 34 | NanoPharmaceuticals LLCINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05489783 | Glioma Developmental and HyperActive Ras Tumor (DHART) Board | recruiting | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06515860 | Neurofibromatosis Type 1 Tumor Early Detection Study(NF1-TED) | enrolling by invitation | — | 1,000 | David MillerOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07793994 | Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors | not yet recruiting | N/A | 130 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796061 | Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)(LIFT) | not yet recruiting | Phase 1 | 45 | Children's National Research InstituteOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02179086 | Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 624 | NRG OncologyOTHER | 2 | Aug 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2026source: clinicaltrials